Loading organizations...
§ Private Profile · Koto, Tokyo, Japan
Develops scalable, high-density cell cultivation for cell and gene therapy, regenerative medicine, and cancer immunotherapy.
CellFiber is a Tokyo, Japan-based biotechnology company that develops scalable biomanufacturing solutions utilizing proprietary hydrogel tube technology for high density cell cultivation. The company provides specialized benchtop extruders, process development services, and technology licensing to address critical scalability challenges in commercial cell and gene therapy manufacturing. Operating within the regenerative medicine and cancer immunotherapy sectors, the firm serves contract development and manufacturing organizations, academic partners, and maintains a network of over 15 active collaborators. CellFiber has secured venture capital backing to scale its global operations, including an approximately JPY 8.3 billion funding round in 2023 featuring investments from Fast Track Initiative and JAFCO. The enterprise is currently led by Chief Executive Officer Yu Yanagisawa, who recently succeeded former President Aki Adachi. The organization was founded in 2015 as a spinoff from the University of Tokyo.
CellFiber has raised $8.6M across 2 funding rounds.
CellFiber has raised $8.6M in total across 2 funding rounds.
CellFiber has raised $8.6M in total across 2 funding rounds.
CellFiber's investors include Kotaro Chiba, Taira Kobayashi, 丸幸弘, 木場 祥介, Daiwa Corporate Investment, Real Tech Fund.
CellFiber has raised $8.6M across 2 funding rounds. Most recently, it raised $5.5M Other Equity in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 9, 2023 | $5.5M Venture Round | — | Kotaro Chiba, Taira Kobayashi, 丸幸弘, 木場 祥介 | Announced |
| May 17, 2022 | $3.1M Series A | Daiwa Corporate Investment, Real Tech Fund | — | Announced |